# Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants

> **NCT00076791** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 66 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Emtricitabine/Tenofovir disoproxil fumarate
- **DRUG:** Tenofovir disoproxil fumarate

## Key facts

- **NCT ID:** NCT00076791
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2010-03
- **Final completion:** 2011-03
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2021-11-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00076791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00076791, "Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00076791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*